Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
IPO Year: 2021
Exchange: NYSE
Website: ginkgobioworks.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2024 | Neutral → Sell | BTIG Research | |
| 5/10/2024 | Mkt Perform → Underperform | William Blair | |
| 11/14/2023 | $3.50 → $2.50 | Outperform → Mkt Perform | Raymond James |
| 11/9/2023 | Buy → Neutral | BTIG Research | |
| 6/2/2023 | $3.00 → $1.25 | Neutral → Sell | Goldman |
| 5/11/2023 | Outperform → Mkt Perform | William Blair | |
| 11/29/2022 | $6.00 | Buy | Berenberg |
| 10/4/2022 | $5.00 | Equal-Weight | Morgan Stanley |
| 5/18/2022 | $3.00 | Neutral → Underperform | BofA Securities |
| 3/2/2022 | $12.00 | Outperform | Cowen |
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
DEFA14A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
DEF 14A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)